Results from the COMBI-d study of 423 patients found the estimated three-year survival rate to be 44% for patients receiving the combination of Tafinlar + Mekinist (95% CI, 36.4%-50.5% ...

Mekinist (trametinib) is a prescription drug that’s used to treat certain types of cancers and tumors. Mekinist comes as a powder that a pharmacist mixes into an oral solution and an oral tablet.

In October, the FDA also granted Breakthrough Therapy designation to Tafinlar in combination with Mekinist for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation ...

Mekinist (trametinib) is a prescription drug that treats specific cancers, including skin, lung, thyroid, and brain. Mekinist’s cost may depend on your dosage, whether you have health insurance ...

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma. Tafinlar (dabrafenib) plus Mekinist (trametinib) continued to be efficacious ...

It is the generic version of Mekinist, a branded product developed by Novartis Pharma AG (NYSE:NVS). As part of the deal, Hikma also entered into a commercial agreement with Novugen under which it ...

Tafinlar and Mekinist combination therapy shows efficacy in glioma treatment for both pediatric and adult patients, with higher response rates in pediatric cases. Objective response rates were 53% for ...

Researchers reported that 34% (95% CI: 30-38%) of all patients in the pooled analysis who were treated with Tafinlar + Mekinist survived at five years 1. Study authors also reported on ...

Trametinib 4.7mg; per bottle; pwd for oral soln after reconstitution; strawberry flavored. In combination with dabrafenib for the treatment of pediatric patients with low-grade glioma (LGG) with a ...

The Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K ...

COMBI-AD is first trial to demonstrate 5- year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma 1 Adjuvant treatment ...